OCULAR THERAPEUTIX, INC Share-based Payment Arrangement, Accelerated Cost
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Payment Arrangement, Accelerated Cost of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2025-11-04
- OCULAR THERAPEUTIX, INC share-based payment arrangement, accelerated cost for the quarter ending 2025-09-30 was $0.00.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, accelerated cost for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, accelerated cost for the quarter ending 2025-03-31 was $1.54M.
- OCULAR THERAPEUTIX, INC share-based payment arrangement, accelerated cost for the quarter ending 2024-09-30 was $0.00.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 9 month |
|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $1.54M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | $1.54M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.54M 10-Q · filed 2025-05-05 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $5.09M derived: sum of 2 quarters · filed 2024-11-14 | $7.49M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $5.09M 10-Q · filed 2024-08-07 | $7.49M 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |